This educational activity is designed to incorporate evidence-based pathophysiology, diagnosis, and/or treatment of urologic disorders into clinical practice. Speakers will utilize their personal, institutional and evidence-based experience to address patient health care conditions requiring clinical and surgical treatment. Speakers will also utilize departmental quality improvement data, M&M data, and patient safety data to improve outcomes of urologic disease and other aspects of urologic patients’ general health. Evidence-based data regarding the changing aspects/newer approaches to surgical disease will be analyzed, and critical issues related to urology within the broader scope of American health care will be discussed. There are varying degrees to individuals’ knowledge regarding clinical and urologic treatments. While individuals may be aware of varied treatment within the urologists’ armamentarium it is beneficial to address the topics from an evidence-based approach.
- Urology Faculty
- Allied Healthcare Providers
- Community Physicians
At the end of this activity, I will be able to:
- To provide historical perspective and background for current controversy regarding testosterone replacement and cardiovascular risks
- To summarize the evidence supporting the increased cardiovascular risk of testosterone replacement
- To summarize the evidence refuting an increased cardiovascular risk of testosterone replacement
Graham Luke Machen, MD
All persons in control of content have no relevant financial relationships to disclose with the exception of the following person:
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.